Clinical Report: Psoriasis–AD Switching May Mimic Treatment Failure
Overview
A multinational retrospective cohort study found that persistent phenotype switching between psoriasis and atopic dermatitis may be misinterpreted as treatment failure. The study included 148 patients across 17 dermatology centers.
Background
Understanding the dynamics between psoriasis and atopic dermatitis is crucial for effective management, as misclassification can lead to inappropriate treatment adjustments. This study addresses treatment-associated phenotype switching during systemic or biologic therapies.
Data Highlights
| Switch Type | Number of Patients | Common Treatments |
|---|---|---|
| Psoriasis to Eczematous | 101 | IL-17 inhibitors (58%) |
| Atopic Dermatitis to Psoriasiform | 47 | Dupilumab (91.5%) |
Key Findings
- 101 patients with psoriasis developed eczematous features during treatment.
- 47 patients with atopic dermatitis developed psoriasiform disease while on treatment.
- Switching from psoriasis to eczematous features was most common with IL-17 inhibitors.
- Dupilumab was the primary treatment associated with atopic dermatitis to psoriasiform switching.
- Janus kinase inhibitors were frequently used for managing switched phenotypes.
- Clinical severity scores improved following treatment modifications in both groups.
Clinical Implications
Physicians should consider the possibility of sustained phenotype switching when patients exhibit opposing features during targeted therapy. This recognition may prevent misclassification as treatment failure and facilitate appropriate therapeutic adjustments.
Conclusion
The study discusses treatment-associated phenotype switching in patients with psoriasis and atopic dermatitis.
Related Resources & Content
- Treatment-associated phenotype switching between psoriasis and atopic dermatitis - PubMed, 2026 -- Study on phenotype switching
- Clinical Rheumatology — Factors Influencing Treatment Switches in Psoriatic Arthritis Patients, 2021
- conexiant — Psoriasis Biologics Face Off in Drug Survival Study
- Dermatology and Therapy — A Narrative Review: Do Systemic Drugs Affect Alzheimer’s Disease?, 2026
- EUROGUIDERM GUIDELINE FOR THE SYSTEMIC, 2025
- Frontiers in Immunology — Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse
- EUROGUIDERM GUIDELINE FOR THE SYSTEMIC
- Treatment-associated phenotype switching between psoriasis and atopic dermatitis - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
